|
US2006166331A1
|
|
Apparatus and method for preparative scale purification of nucleic acids
|
|
US2003064951A1
|
|
Methods for purifying nucleic acids
|
|
AU1542802A
|
|
IL-2 gene expression and delivery systems and uses
|
|
AU9715701A
|
|
Insulin-like growth factor I (IGF-I) expression system and methods of use
|
|
AU8724001A
|
|
Gene expression and delivery systems and uses
|
|
WO02061040A2
|
|
Gene delivery formulations and methods for treatment of ischemic conditions
|
|
AU9635401A
|
|
Improved system for regulation of transgene expression
|
|
WO02097099A1
|
|
Regulated expression of ghrh
|
|
AU4542701A
|
|
Nucleic acid formulations for gene delivery and methods of use
|
|
BR0108959A
|
|
Improved poloxamer or poloxamine compositions for nucleic acid delivery
|
|
US2001034435A1
|
|
Process and equipment for plasmid purification
|
|
AU6389000A
|
|
Sonoporation of tumors
|
|
WO0040692A2
|
|
Methods and compositions for delivering nucleic acids
|
|
US6649780B1
|
|
Cationic lipids
|
|
AU1523900A
|
|
Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
|
|
AU5345999A
|
|
Protected one-vial formulation for nucleic acid molecules, methods of making thesame by in-line mixing, and related products and methods
|
|
CA2337496A1
|
|
Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
|
|
AU4863899A
|
|
Methods for purifying nucleic acids
|
|
EP1086239A1
|
|
Formulations for electroporation
|
|
AU4214099A
|
|
Cytokine resistant cytomegalovirus promoter mutants and related products and methods
|
